Nicholas Donoghoe on clinical trials
From AbbVie's Nicholas Donoghoe on Innovation in Drug Development Process · · AbbVie
“That blueprint is 50% faster. We took a trial that used to be four years and made it two.”
On , Nicholas Donoghoe, Executive VP and Chief Business & Strategy Officer at AbbVie, spoke about clinical trials during AbbVie's Nicholas Donoghoe on Innovation in Drug Development Process on AbbVie.
About Nicholas Donoghoe
At the Atlantic’s 2023 Progress Summit in Chicago, Nicholas Donoghoe, Executive Vice President and Chief Business and Strategy Officer at AbbVie, discussed the company’s efforts to innovate the drug development process. He described AbbVie’s use of automation and robotics to make the manufacturing of medicine less linear and more parallel, stating that this approach allowed the company to make medicines available a year sooner. Donoghoe also said AbbVie applied artificial intelligence and machine learning to its clinical trial data, which he described as a "gold mine of information," and that the resulting blueprint reduced trial durations by 50%, citing examples of a four-year trial shortened to two years and a three-year trial shortened to a year and a half. Donoghoe also addressed patient support, noting that AbbVie built a team of nurses to answer questions from complex patients about side effects, insurance, and access, because "not everybody has a doctor in their family to call." He concluded by discussing AbbVie’s ambition to tackle conditions such as spinal cord injury, stroke, and Alzheimer’s, and challenged attendees to pursue their own big ideas by working across disciplines.